Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan combination therapy in first-line advanced or metastatic NSCLC without actionable genomic alterations
2021-004280-27Phase 2Active
- Sponsor
- Gilead Sciences
- Start
- Feb 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab govitecan, pembrolizumab, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Objective response rate. Started Feb 2022; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-004280-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004280-27.